Search

Copyright of Evaluation & Analysis of Drug-Use in Hospitals of China is the property of Evaluation & Analysis of Drug-Use in Hospitals of China Editorial Board and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Evaluation & Analysis of Drug-Use in Hospitals of China is the property of Evaluation & Analysis of Drug-Use in Hospitals of China Editorial Board and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Evaluation & Analysis of Drug-Use in Hospitals of China is the property of Evaluation & Analysis of Drug-Use in Hospitals of China Editorial Board and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Evaluation & Analysis of Drug-Use in Hospitals of China is the property of Evaluation & Analysis of Drug-Use in Hospitals of China Editorial Board and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Evaluation & Analysis of Drug-Use in Hospitals of China is the property of Evaluation & Analysis of Drug-Use in Hospitals of China Editorial Board and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Evaluation & Analysis of Drug-Use in Hospitals of China is the property of Evaluation & Analysis of Drug-Use in Hospitals of China Editorial Board and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Evaluation & Analysis of Drug-Use in Hospitals of China is the property of Evaluation & Analysis of Drug-Use in Hospitals of China Editorial Board and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

OBJECTIVE: To probe into the efficacy of Escitalopram oxalate tablets combined with modified electroconvulsive therapy (MECT) in patients with bipolar disorder and depressive episode and its effects on serum brain-derived neurotrophic factor (BDNF). METHODS: This study was a prospective randomized controlled trial, which started in Mar. 2019 and ended in Oct. 2020. A total of 114 patients with bipolar disorder and depressive episode admitted into Jining Psychiatric Hospital were extracted, and the sample size was determined by the sample size of the superiority test. Excel function was used to generate 114 random numbers, and patients were assigned according to the order of admission. Odd and even numbers were set as control group and study group respectively. During the clinical investigation, there were 7 cases of missed and lost follow-up, and 107 cases completed the experiment, including 53 cases in the control group and 54 cases in the study group. The control group was treated with MECT, while the study group received Escitalopram oxalate tablets combined with MECT. The depression status of two groups before treatment and after treatment of 8 weeks was evaluated by Hamilton Depression Scale-17 (HAMD-17), and the serum BDNF level was detected, cognitive function was assessed by Trail Making Test (TMT), the efficacy was evaluated and the incidence of adverse drug reactions was analyzed. RESULTS: The total effective rate of the study group was 92. 59% (50/54), significantly higher than 71. 70% (38/53) of the control group, with statistically significant difference (P<0. 05). After treatment, the HAMD-17 score of two groups was significantly lower than that before treatment, and the HAMD-17 score of the study group as lower than that of the control group, with statistically significant difference (P<0. 05). After treatment, the serum BDNF level of two groups was significantly higher than that before treatment, and the serum BDNF level of the study group was significantly higher than that of the control group, with statistically significant difference (P<0. 05). After treatment, TMT-A and TMT-B of two groups were significantly shorter than those before treatment, and those of the study group were significantly shorter than those of the control group, with statistically significant difference (P < 0. 05). There was no significant difference in the incidence of headache, nausea, vomiting, dizziness, short-term memory disorder between two groups (P > 0. 05). CONCLUSIONS: The efficacy of Escitalopram oxalate tablets combined with MECT in patients with bipolar disorder and depressive episode is significant, which can significantly alleviate the depression, effectively increase the level of BDNF and improve the cognitive function with higher safety. [ABSTRACT FROM AUTHOR]

OBJECTIVE: To evaluate the efficacy, safety and economy of icodextrin peritoneal dialysate based on rapid health technology assessment (HTA), so as to provide evidence-based medical-evidence information for clinical decision-makers. METHODS: PubMed, Embase, the Cochrane Library, CNKI, Wanfang Data and the official website of HTA institutions were searched systematically (the retrieval time was from the establishment of the database to Jun. 2022) to collect HTA reports, systematic review / Meta-analysis, and pharmacoeconomic studies related to icodextrin peritoneal dialysate. According to inclusion and exclusion criteria, two researchers independently screened articles, evaluated quality and extracted data, and qualitative analysis was performed on the data results. RESULTS: A total of 6 systematic review / Meta-analysis and 1 economic study were included. (1) In terms of effectiveness, compared with glucose peritoneal dialysis liquid, icodextrin peritoneal dialysate could significantly increase the ultrafiltration volume and peritoneal urea clearance rate, reduce free fatty acids and reduce the risk of ultrafiltration failure in patients during prolonged abdominal retention. (2) In terms of safety, the incidence of peritonitis associated with peritoneal dialysis and the incidence of total adverse drug reactions were not inferior to those of icodextrin peritoneal dialysate. (3) In terms of economics, icodextrin peritoneal dialysate was economical under the premise that it could delay the time of patients transferring from peritoneal dialysis to hemodialysis. CONCLUSIONS: Icodextrin peritoneal dialysate has good efficacy and safety in clinical treatment of peritoneal dialysis patients, but whether it is economic needs more relevant studies. [ABSTRACT FROM AUTHOR]

OBJECTIVE: To explore the effects of clinical pharmacists in the management of drug therapy during the treatment of patients with digoxin, so as to promote the rational application of digoxin. METHODS: The analysis report of blood concentration monitoring results by clinical pharmacists, clinical diagnosis and treatment data of 637 inpatients with digoxin were analyzed retrospectively. RESULTS: Among the 637 patients, there were 107 cases (16.80%) with the blood concentration of digoxin <0.5 ng/ml, 349 cases (54.79%) with the blood concentration of digoxin as the effective treatment blood concentration (0.5-2.0 ng/ml), and 181 cases (28.41%) of digoxin blood concentration >2.0 ng/ml. The blood drug concentration of goxin was affected by patient’s age, gender, renal function, drug combination and other factors. Clinical pharmacists provided individualized pharmaceutical services for patients, which improved the efficacy and reduced the incidence of adverse drug reactions. CONCLUSIONS: Clinical pharmacists actively carry out individualized pharmacy service during the treatment of patients with digoxin, promote the rational application of digoxin, improve the level of drug therapy, and ensure the medical safely. [ABSTRACT FROM AUTHOR]